LAWRENCE, Mass.,
March 15, 2018
/PRNewswire/ -- NxStage Medical, Inc.
(Nasdaq: NXTM), the manufacturer of the NxStage® System One™
home hemodialysis system, is celebrating the fifth annual Home
Hemodialysis (HHD) Day on March 15,
2018. Annually observed during National Kidney Month, this
initiative focuses on raising awareness of home hemodialysis and
more frequent therapy as a viable treatment option for patients
requiring dialysis. Boston's
iconic Zakim Bridge will be cast in green light on the evening of
March 15th to commemorate HHD
Day.
![NxStage Medical, Inc. (PRNewsFoto/NxStage Medical, Inc.) NxStage Medical, Inc. (PRNewsFoto/NxStage Medical, Inc.)](https://mma.prnewswire.com/media/321808/nxstage_medical__inc__logo.jpg)
"We are proud to continue this tradition of generating
awareness of home hemodialysis for the fifth consecutive year,"
said Joseph Turk, President of
NxStage. "Home hemodialysis is an important therapy option for
patients suffering with kidney disease. It allows patients to
have greater control over their treatment and schedule. And
the home is the most practical setting for individualized care and
innovative treatment options, such as more frequent hemodialysis,
which have been shown to have significant clinical benefits.
More frequent hemodialysis is associated with: 13% lower risk of
death compared to traditional in-center hemodialysis,1
11% reduction in left ventricular hypertrophy, reducing stress on
the heart,2,3 and an 87% improvement in recovery time
after treatment.4 We hope this HHD Day will help more
kidney patients reclaim their lives by talking with their doctors
about home hemodialysis and more frequent home
hemodialysis."
NxStage is also requesting that patients and their care
partners share their stories on social media and update their
Facebook profile picture frame to show their support of home
hemodialysis.
For more information about HHD Day or NxStage products and
services, please visit www.facebook.com/NxStage or
www.nxstage.com.
About the NxStage System One
The NxStage System One is the first and only truly portable
hemodialysis system cleared specifically by the FDA for home
hemodialysis, home nocturnal hemodialysis and solo home
hemodialysis. Its simplicity and revolutionary size (just over a
foot tall) are intended to allow convenient use in patients' homes
and give patients the freedom to travel with their therapy. When
combined with the NxStage PureFlow SL Dialysis Preparation System,
patients are able to further simplify, using ordinary tap water to
create dialysis fluid on demand. Unlike conventional hemodialysis
systems, the System One requires no special infrastructure to
operate. Under the guidance of their physician, patients can use
the NxStage System One, with their trained partners (or for
patients prescribed to receive solo dialysis, alone), where, how
and when it best meets their needs, including while they are
sleeping - at home or on vacation and at a medically appropriate
treatment frequency. In addition, NxStage's Nx2me Connected Health
platform collects important NxStage System One and patient
information for flexible viewing, monitoring and reporting that may
improve patient management and patient retention, as well as
simplify alternative site care. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical
technology company, headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
ESRD and acute kidney failure. NxStage also has established a small
number of dialysis clinics. For more information on NxStage and its
products and services, please visit the Company's websites at
www.nxstage.com and www.nxstagekidneycare.com.
The NxStage System One is a prescription device and,
like all medical devices, involves some risks. The risks associated
with hemodialysis treatments in any environment include, but are
not limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream, and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments
at home are done without the presence of medical personnel and
on-site technical support. Patients and their partners must be
trained on what to do and how to get medical or technical help if
needed. Patients should consult with their doctor to
understand the risks and responsibilities of home and/or more
frequent hemodialysis using the NxStage System One. Additionally,
the reported benefits of home and/or more frequent hemodialysis may
not be experienced by all patients.
Forward-Looking Statements
This
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements contained in this release that are not clearly
historical in nature are forward-looking, and the words
"anticipate," "believe," "expect," "estimate," "plan," and similar
expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors including those that are discussed in
NxStage's filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended
December 31, 2017. NxStage is under
no obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
References:
1. Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins
AJ. Survival in daily home hemodialysis and matched thrice-weekly
in-center hemodialysis patients. J Am Soc Nephrol.
2012;33(5):895-904.
2. FHN Trial Group. In-center hemodialysis six times per
week versus three times per week. N Engl J Med.
2010;363(24):2287-2300.
3. Culleton BF, Pannier B, Guerin AP, et al. Alterations
of left ventricular hypertrophy in and survival of patients
receiving hemodialysis: follow-up of an interventional study. J Am
Soc Nephrol. 2001;12(12):2759-2767.
4. Jaber BL, Lee Y, Collins AJ, et al. Effect of daily
hemodialysis on depressive symptoms and post dialysis recover time:
interim report from the FREEDOM (Following Rehabilitation,
Economics and Everyday-Dialysis Outcome Measurements) Study. Am J
Kidney Dis. 2010;56(3):531-539.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nxstage-celebrates-fifth-annual-national-home-hemodialysis-day-300614386.html
SOURCE NxStage Medical, Inc.